Atara Biotherapeutics (ATRA) Net Cash Flow (2013 - 2026)

Atara Biotherapeutics' Net Cash Flow history runs 14 years deep, the most recent figure standing at -$122000.0 for Q1 2026.

• Quarterly Net Cash Flow rose 98.91% year-over-year to -$122000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.6 million (up 73.52% YoY) and the FY2025 annual result came in at -$16.7 million, down 1958.45% from the prior year.
• Net Cash Flow was -$122000.0 for Q1 2026 at Atara Biotherapeutics, down from $2.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $26.6 million in Q4 2022 and bottomed at -$44.2 million in Q1 2023.
• A 5-year average of -$5.8 million and a median of -$3.8 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 473.73% — and 2023, when it plunged 890.39%.
• Atara Biotherapeutics' Net Cash Flow stood at $26.6 million in 2022, then sank by 246.27% to -$38.9 million in 2023, then soared by 45.0% to -$21.4 million in 2024, then jumped by 112.79% to $2.7 million in 2025, then sank by 104.45% to -$122000.0 in 2026.
• Business Quant data shows ATRA's Net Cash Flow at -$122000.0 in Q1 2026, $2.7 million in Q4 2025, and -$11.2 million in Q3 2025.